Further, BCL-xL has been implicated in CML progression to BP [25], and BCL-2 and BCL-xL dependence are associated with a more immature immune cell phenotype [26, 27]. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.